Home › Funds › IQ EQ FUND MANAGEMENT (IRELAND) Ltd › NTLA

IQ EQ FUND MANAGEMENT (IRELAND) Ltd position in NTLA

INTELLIA THERAPEUTICS INC · Health Care

IQ EQ FUND MANAGEMENT (IRELAND) Ltd reported holding 777,948 shares of NTLA (INTELLIA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$13.2M, representing 0.84% of its reported portfolio and ranking #34 among its reported holdings. IQ EQ FUND MANAGEMENT (IRELAND) Ltd has disclosed NTLA holdings in 9 of the last 9 reported quarters, going back to Q2 2024.

Latest position (Q2 2026)777.95K sh
Reported value held$13.16M
Portfolio Weight0.84%
First reportedQ2 2024
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How IQ EQ FUND MANAGEMENT (IRELAND) Ltd's NTLA position evolved

IQ EQ FUND MANAGEMENT (IRELAND) Ltd first disclosed a stake in NTLA in Q2 2024 at 13,142 shares (US$294K). The position peaked in Q2 2026 at 777,948 shares, worth US$13.2M. Across 9 filings, IQ EQ FUND MANAGEMENT (IRELAND) Ltd increased the stake 7 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 777,948 shares valued at US$13.2M — an increase of 53,662 shares quarter over quarter.. Notable position changes include a 137% increase in Q4 2024 (shares fell 39% over the following quarter), a 94% increase in Q1 2025 (shares rose 32% over the following quarter), a 177% increase in Q2 2025 (shares rose 84% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 13.14K $294.12K New
Q3 2024 23.03K $473.29K Add
Q4 2024 54.66K $637.30K Add
Q1 2025 106.21K $755.15K Add
Q2 2025 294.39K $2.76M Add
Q3 2025 494.47K $8.54M Add
Q4 2025 731.42K $6.58M Add
Q1 2026 724.29K $9.29M Reduce
Q2 2026 777.95K $13.16M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NTLA and 13F data

NTLA (INTELLIA THERAPEUTICS INC) is a Health Care company. 38 other funds we track also report a position in NTLA — the largest reported positions include ARK Invest (US$285.5M), RA CAPITAL MANAGEMENT, L.P. (US$76.6M), REGENERON PHARMACEUTICALS, INC. (US$62.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NTLA

All NTLA fund holders →

FAQ

How long has IQ EQ FUND MANAGEMENT (IRELAND) Ltd held NTLA?

IQ EQ FUND MANAGEMENT (IRELAND) Ltd has disclosed NTLA holdings in 9 of the last 9 reported quarters, going back to Q2 2024.

What is IQ EQ FUND MANAGEMENT (IRELAND) Ltd's current position in NTLA?

As of Q2 2026, IQ EQ FUND MANAGEMENT (IRELAND) Ltd holds 777.95K shares of NTLA (INTELLIA THERAPEUTICS INC), valued at $13.16M, representing 0.84% of its reported portfolio and ranking #34.

Has IQ EQ FUND MANAGEMENT (IRELAND) Ltd been buying or selling NTLA?

In the latest 13F filing (Q2 2026), IQ EQ FUND MANAGEMENT (IRELAND) Ltd increased its position in NTLA. The position peaked in Q2 2026 at 777.95K shares.

Which other funds hold NTLA?

Other major institutional holders of NTLA include ARK Invest, RA CAPITAL MANAGEMENT, L.P., REGENERON PHARMACEUTICALS, INC., among 38 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.